Key result
ApoC-III SstI polymorphism linked to ~29% higher fasting triglycerides versus S1/S1 homozygotes.
Why the study?
Do apoC-III gene polymorphisms affect fasting plasma lipoprotein-lipid levels and OGTT response in viscerally obese men?
Cross-Sectional (n=122)
Do apoC-III gene polymorphisms affect fasting plasma lipoprotein-lipid levels and OGTT response in viscerally obese men?
Answers are grounded in this paper and cite their sources.
The apoC-III SstI polymorphism is associated with hypertriglyceridemia and smaller, denser LDL particles in viscerally obese men, potentially exacerbating their dyslipidemic state.
Abdominal visceral adipose tissue (AT) accumulation is associated with an atherogenic metabolic profile that includes increased plasma triglyceride (TG), low HDL cholesterol levels, and an insulin-resistant hyperinsulinemic state. Whereas the apolipoprotein (apo) C-III C3238G gene variant, often referred to as the SstI polymorphism, has been related to variations in plasma TG concentrations, another variation within the insulin responsive element (C-482T) of the apoC-III gene has been associated with greater glucose and insulin responses to an oral glucose tolerance test (OGTT); however, these results were obtained in nonobese individuals. We therefore investigated the effects of three apoC-III gene polymorphisms, namely SstI, C-482T, and T-455C, on fasting plasma lipoprotein-lipid levels and response to a 75 g OGTT in a sample of 122 viscerally obese men (abdominal visceral AT area >or=130 cm(2)). Among the three gene variants that were examined, the SstI variation was the only one found to be associated with hypertriglyceridemia. Indeed, S1/S2 heterozygotes (n = 24) were characterized by increased fasting plasma TG concentrations compared with S1/S1 homozygotes (n = 98) (mean +/- SD: 3.03 +/- 1.58 vs. 2.34 +/- 0.95 mmol/l respectively, P < 0.05). The higher TG concentrations in S1/S2 were associated with the presence of smaller, denser LDL particles compared with S1/S1 subjects (LDL peak particle diameter: 24.8 +/- 0.5 nm vs. 25.1 +/- 0.5 nm respectively, P < 0.05). Furthermore, there was no association between the response to the OGTT and any of the apoC-III gene variants (SstI, T-455C, or C-482T) examined. Results of the present study support the notion of a hypertriglyceridemic effect associated with the apoC-III SstI polymorphism that could modulate the magnitude of the dyslipidemic state in abdominally obese patients.
No takes yet. Share an insight, caveat, or question.
Couillard et al. (2003) conducted a cross-sectional in Visceral obesity (n=122). apoC-III SstI polymorphism (S1/S2 heterozygotes) vs. S1/S1 homozygotes was evaluated on Fasting plasma triglyceride concentrations (mmol/l) (p=<0.05). The apoC-III SstI polymorphism (S1/S2 heterozygotes) was associated with higher fasting plasma triglyceride concentrations compared with S1/S1 homozygotes (3.03 vs 2.34 mmol/l; P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: